{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:51:21Z","timestamp":1791280281933,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.eururo.2008.01.013","type":"journal-article","created":{"date-parts":[[2008,1,16]],"date-time":"2008-01-16T12:14:41Z","timestamp":1200485681000},"page":"621-630","source":"Crossref","is-referenced-by-count":34,"title":["Celecoxib has Potent Antitumour Effects as a Single Agent and in Combination with BCG Immunotherapy in a Model of Urothelial Cell Carcinoma"],"prefix":"10.1016","volume":"54","author":[{"given":"Simon J.","family":"Dovedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry R.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hing","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2008.01.013_bib1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.01.013_bib2","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","article-title":"T-cell subsets required for intravesical BCG immunotherapy for bladder cancer","volume":"150","author":"Ratliff","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.01.013_bib3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/0952-7915(94)90128-7","article-title":"Role of cytokines in determining T-lymphocyte function","volume":"6","author":"O\u2019Garra","year":"1994","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.eururo.2008.01.013_bib4","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/S0022-5347(05)65522-X","article-title":"T helper 1\/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer","volume":"166","author":"Saint","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.01.013_bib5","first-page":"1030A","article-title":"Maturation of the cytokine immune response to BCG in the bladder: implications for treatment schedules","volume":"155","author":"O\u2019 Donnell","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.01.013_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1365-2249.2002.01734.x","article-title":"IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer","volume":"127","author":"Riemensberger","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.eururo.2008.01.013_bib7","first-page":"5647","article-title":"Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder","volume":"59","author":"Mohammed","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2008.01.013_bib8","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1158\/0008-5472.CAN-04-3671","article-title":"Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade","volume":"65","author":"Wang","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2008.01.013_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nm0302-289","article-title":"Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy","volume":"8","author":"Pai","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2008.01.013_bib10","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.1158\/0008-5472.CAN-05-0216","article-title":"Prostaglandin E2 activates mitogen-activated protein kinase\/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner","volume":"65","author":"Krysan","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2008.01.013_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/gut.2004.047100","article-title":"Prostaglandins and cancer","volume":"55","author":"Wang","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.eururo.2008.01.013_bib12","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/01.ju.0000161589.85869.ae","article-title":"Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus Calmette-Guerin immunotherapy for bladder cancer","volume":"174","author":"Dovedi","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.01.013_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0009-8981(95)06031-1","article-title":"Urinary creatinine adjusted reference ranges for homovanillic and vanillylmandelic acid in children and adults","volume":"236","author":"Cole","year":"1995","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.eururo.2008.01.013_bib14","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2008.01.013_bib15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1054\/plef.2002.0383","article-title":"Dendritic cells produce eicosanoids, which modulate generation and functions of antigen-presenting cells","volume":"66","author":"Harizi","year":"2002","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.eururo.2008.01.013_bib16","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0022-5347(01)67113-1","article-title":"Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy","volume":"154","author":"Esuvaranathan","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.01.013_bib17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1365-2249.2003.02071.x","article-title":"Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity","volume":"131","author":"Nadler","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.eururo.2008.01.013_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00002371-200403000-00005","article-title":"Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma","volume":"27","author":"Arnold","year":"2004","journal-title":"J Immunother"},{"key":"10.1016\/j.eururo.2008.01.013_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.urology.2005.03.052","article-title":"Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model","volume":"66","author":"Horinaga","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2008.01.013_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2249.2004.02522.x","article-title":"Recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity","volume":"137","author":"Luo","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.eururo.2008.01.013_bib21","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1097\/01.ju.0000109742.88380.a2","article-title":"Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity","volume":"171","author":"O\u2019Donnell","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.01.013_bib22","doi-asserted-by":"crossref","first-page":"813","DOI":"10.4049\/jimmunol.175.2.813","article-title":"Cyclooxygenase 2 inhibition promotes IFN-{gamma}-dependent enhancement of antitumor responses","volume":"175","author":"Sharma","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.eururo.2008.01.013_bib23","first-page":"7845","article-title":"Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy","volume":"63","author":"DeLong","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2008.01.013_bib24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.urology.2005.02.024","article-title":"NS-398, a selective cyclooxygenase-2 inhibitor, reduces experimental bladder carcinoma outgrowth by inhibiting tumor cell proliferation","volume":"66","author":"Smakman","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2008.01.013_bib25","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Gu\u00e9rin (BCG) in patients with non\u2013muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.01.013_bib26","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.eururo.2007.03.006","article-title":"Interview with Dr Richard Sylvester: transition cell carcinoma of the bladder","volume":"51","author":"McKillop","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.01.013_bib27","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283808000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283808000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T20:30:15Z","timestamp":1557174615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283808000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0302283808000171"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2008.01.013","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}